<!DOCTYPE html>
<html>
<head>
    <meta name="HandheldFriendly" content="true"/>
    <meta name="MobileOptimized" content="320"/>
    <meta name="viewport" content="initial-scale=1.0, width=device-width, user-scalable=yes"/>
    <meta charset="utf-8">
    <title>KDOQI Guidelines, ACE/ARB in CKD</title>
    <meta name="author" content="doakey3">
    <link rel="icon" type="image/svg+xml" href="favicon.svg">
    <meta name="description" content="Guidelines for using ACE and ARBs in chronic kidney disease.">
    <meta name="keywords" content="kdoqi, chronic, kidney, disease, ckd, blood, pressure, hypertension, renal, failure, ace, acei, angiotensin, converting, enzyme, inhibitor, receptor, blocker, arb">

    <style>
        body {
            font-family: arial;
        }
        table {
            border-collapse: collapse;
        }
        h2 {
            font-size: 125%;
        }
        td, th {
            padding: 10px;
            vertical-align: top;
            border: 1px solid black;
        }
    </style>

</head>

<body>
    <h2>General Principles for Monitoring for Adverse Effects When Initiacing ACE Inhibitors or ARBs</h2>
    <ol>
        <li>Measure "baseline" blood pressure, GFR, and serum potassium</li>
        <li>Determine interval for follow-up measurements</li>
        <li>Counseling to reduce risk of hypotension</li>
        <li>Counseling to reduce risk of early GFR decrease</li>
        <li>Counseling to reduce risk of hyperkalemia</li>
        <li>Counseling for allergic reactions</li>
        <li>Counseling women of child-bearing potential about adverse effects on the fetus</li>
    </ol>
    
    <hr>
    
    <h2>Circumstances in which ACE Inhibitors and ARBs Should Not Be Used</h2>
    <table>
        <tr>
            <th></th>
            <th>Do Not Use</th>
            <th>Use with Caution</th>
        </tr>
        <tr>
            <th>ACE Inhibitor</th>
            <td>Pregnancy (A)<br>History of angioedema (A)<br>Cough due to ACE inhibitors (A)<br>Allergy to ACE or ARB (A)</td>
            <td>Women not practicing contraception (A)<br>Bilateral renal artery stenosis* (A)<br>Drugs causing hyperkalemia (A)</td>
        </tr>
        <tr>
            <th>ARB</th>
            <td>Allergy to ACE inhibitor or ARB (A)<br>Pregnancy (C)<br>Cough due to ARB (C)</td>
            <td>Bilateral renal artery stenosis* (A)<br>Drugs causing hyperkalemia (A)<br>Women not practicing contraception<br>Angioedema due to ACE inhibitors (C)</td>
        </tr>
    </table>
    <span style="font-size: 75%;">*Including renal artery stenosis in the kidney transplant or in a solitary kidney.</span>
    
    <hr>
    
    <h2>Recommended Intervals for Monitoring Blood Pressure, GFR and Serum Potassium for Side Effects of ACE Inhibitors or ARBs in CKD</h2>
    <table>
        <tr>
            <th rowspan="4">Baseline Value</th>
            <th>SBP (mmHg)</th>
            <td>&ge;120</td>
            <td>&lt;120</td>
        </tr>
        <tr>
            <th>GFR (mL/min/1.73 m^2)</th>
            <td>&ge;60</td>
            <td>&lt;60</td>
        </tr>
        <tr>
            <th>Early GFR Decline (%)</th>
            <td>&lt;15</td>
            <td>&ge;15</td>
        </tr>
        <tr>
            <th>Serum Potassium (mEq/L)</th>
            <td>&le;4.5</td>
            <td>&gt;4.5</td>
        </tr>
        
        <tr>
            <th rowspan="2">Interval</th>
            <th>After initiation or increase in dose of ACE inhibitor or ARB</th>
            <td>4-12 weeks</td>
            <td>&le;4 weeks</td>
        </tr>
        <tr>
            <th>After blood pressure is at goal and dose is stable</th>
            <td>6-12 months</td>
            <td>1-6 months</td>
        </tr>
    </table>
    
    <hr>
    <h2>Summary of Recommended Intervals to Monitor for Side Effects after Initiation or Change in Dose of ACE Inhibitor or ARB Therapy According to Baseline Values</h2>
    <table>
        <tr>
            <th rowspan="4">Baseline Value</th>
            <td>SBP (mmHg)</td>
            <td>&ge;120</td>
            <td>110-119</td>
            <td>&lt;110</td>
        </tr>
        <tr>
            <td>Baseline GFR (mL/min/1.73 m^2)</td>
            <td>&ge;60</td>
            <td>30-59</td>
            <td>&lt;30</td>
        </tr>
        <tr>
            <td>Early GFR Decline (%)</td>
            <td>&lt;15</td>
            <td>15-30</td>
            <td>&gt;30</td>
        </tr>
        <tr>
            <td>Serum Potassium (mEq/L)</td>
            <td>&le;4.5</td>
            <td>4.6-5.0</td>
            <td>&gt;5.0</td>
        </tr>
        <tr>
            <th colspan="2">Interval (weeks)</th>
            <td><b>4-12</b></td>
            <td><b>2-4</b></td>
            <td><b>&le;2</b></td>
        </tr>
    </table>
    
    <hr>
    
    <h2>Summary of Recommended Intervals to Monitor for Side Effects of ACE Inhibitor or ARB Therapy after Blood Pressure is at Goal and Dose is Stable, According to Baseline Values</h2>
    <table>
        <tr>
            <th rowspan="4">Baseline Value</th>
            <th>SBP (mmHG)</th>
            <td>120-129</td>
            <td>110-119</td>
            <td>&lt;110</td>
        </tr>
        <tr>
            <th>GFR (mL/min/1.73 m^2)</th>
            <td>&ge;60</td>
            <td>30-59</td>
            <td>&lt;30</td>
        </tr>
        <tr>
            <th>Early GFR Decline (%)</th>
            <td>&lt;15</td>
            <td>&lt;15</td>
            <td>&ge;15</td>
        </tr>
        <tr>
            <th>Potassium (mEq/L)</th>
            <td>&le;4.5</td>
            <td>4.6-5.0</td>
            <td>&gt;5.0</td>
        </tr>
        <tr>
            <th colspan="2">Interval (Months)</th>
            <td>6-12</td>
            <td>3-6</td>
            <td>1-3</td>
        </tr>
    </table>
    
    <hr>

    <h2>Recommended Intervals for Monitoring GFR According to Baseline GFR</h2>
    <table>
        <tr>
            <th></th>
            <th>GFR &ge;60</th>
            <th>GFR 30-59</th>
            <th>GFR &lt;30</th>
        </tr>
        <tr>
            <th>After initiation or changes in dose of antihypertensive therapy</th>
            <td>4-12 weeks</td>
            <td>2-4 weeks</td>
            <td>&le;2 weeks</td>
        </tr>
    </table>
    
    <hr>
    
    <h2>Changes in Management Based on Magnitude of Early Decrease in GFR</h2>
    <table>
        <tr>
            <th></th>
            <th>0-15%</th>
            <th>15-30%</th>
            <th>30-50%</th>
            <th>&gt;50%</th>
        </tr>
        <tr>
            <th>Dosage adjustment for ACEi and ARB</th>
            <td>None</td>
            <td>None</td>
            <td>Reduce</td>
            <td>Discontinue</td>
        </tr>
        <tr>
            <th>Recommended interval for monitoring GFR</th>
            <td>As per GFR (previous table)</td>
            <td>One after 10-14 days. If repeat GFR remains within 15-30% of baseline value, resume monitoring schedule as per GFR (previous table)</td>
            <td>Every 5-7 days until GFR is within 30% of baseline value</td>
            <td>Every 5-7 days until GFR is within 15% of baseline value</td>
        </tr>
        <tr>
            <th>Evaluate for causes of decreased GFR (including consideration of RAD, see Guideline 4)</th>
            <td>No</td>
            <td>No</td>
            <td>Yes</td>
            <td>Yes</td>
        </tr>
    </table>
    
    <hr>
    
    <h2>Recommendations for Prevention and Management of Hyperkalemia, According to Baseline Serum Potassium</h2>
    <table>
        <tr>
            <th></th>
            <th>&le;4.5</th>
            <th>4.6-5.0</th>
            <th>5.1-5.5</th>
            <th>&gt;5.5</th>
        </tr>
        <tr>
            <td>Education to avoid high potassium foods</td>
            <td>No</td>
            <td>Yes</td>
            <td>Yes</td>
            <td>Yes</td>
        </tr>
        <tr>
            <td>Measures to lower serum potassium</td>
            <td>No</td>
            <td>No</td>
            <td>Simultaneous with initiation</td>
            <td>Prior to initiation</td>
        </tr>
        <tr>
            <td>Recommended interval for monitoring serum potassium after initiation or change in dose of antihypertensive therapy</td>
            <td>4-12 weeks</td>
            <td>2-4 weeks</td>
            <td>&lg;2 weeks</td>
            <td>&le;2 weeks</td>
        </tr>
    </table>
</body>
</html>
